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Abstract Axial myopathy is a rare neuromuscular dis-
ease that is characterized by paraspinal muscle atrophy and
abnormal posture, most notably camptocormia (also known
as bent spine). The genetic cause of familial axial myop-
athy is unknown. Described here are the clinical features
and cause of late-onset predominant axial myopathy and
encephalopathy. A 73-year-old woman presented with a
10-year history of severe paraspinal muscle atrophy and
cerebellar ataxia. Her 84-year-old sister also developed
late-onset paraspinal muscle atrophy and generalized sei-
zures with encephalopathy. Computed tomography showed
severe atrophy and fatty degeneration of their paraspinal
muscles. Their mother and maternal aunt also developed
bent spines. The existence of many ragged-red ﬁbers and
cytochrome c oxidase-negative ﬁbers in the biceps brachii
muscle of the proband indicated a mitochondrial abnor-
mality. No signiﬁcant abnormalities were observed in the
respiratory chain enzyme activities; however, the activities
of complexes I and IV were relatively low compared with
the activities of other complexes. Sequence analysis of the
mitochondrial DNA from the muscle revealed a novel
heteroplasmic mutation (m.602C[T) in the mitochondrial
tRNA
Phe gene. This familial case of late-onset predominant
axial myopathy and encephalopathy may represent a new
clinical phenotype of a mitochondrial disease.
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Introduction
Camptocormia, a term coined by Souques and Rosanoff-
Saloff from two Greek words (kamptos meaning bent and
kormos meaning trunk), is characterized by involuntary
trunk ﬂexion in the erect position that disappears in the
supine position. Camptocormia was initially described as a
hysterical phenomenon that occurred in male soldiers
during World Wars I and II [1, 16]. However, in the last
20 years camptocormia has been reported to be present
with various organic diseases, including muscular dystro-
phies, inﬂammatory myopathies, dystonia, amyotrophic
lateral sclerosis, myasthenia gravis, paraneoplastic syn-
drome, Parkinson’s disease, multiple system atrophy, and
spinal deformities, as well as in an idiopathic form.
Camptocormia is also referred to as ‘‘bent spine syndrome’’
[1, 32].
Axial myopathy has been described as the selective
involvement of the paraspinal muscles in camptocormia or
dropped head. Axial myopathy has heterogeneous etiolo-
gies, including primary and various other neuromuscular
disorders. Primary axial myopathy is characterized by the
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of the spine, normal or slightly elevated serum creatine
kinase (CK) levels, and a myogenic pattern on electro-
myography in the elderly. Muscle biopsies show
nonspeciﬁc myopathic changes with ﬁbrosis, fatty
replacement, and variations in ﬁber size. In addition, some
ragged-red ﬁbers and complex I and III deﬁciencies have
been observed; these ﬁndings are considered to be the age-
related accumulation of various mitochondrial abnormali-
ties [21, 31].
Somecasesofautosomaldominantinheritancepatternsof
familialprimaryaxialmyopathywerereportedseveralyears
ago; however, the genetic analyses that were used have not
been described [31]. Recently, a novel heterozygous domi-
nantmutationintheskeletalmuscleryanodinereceptorgene
was identiﬁed in the central cores of muscle biopsy speci-
mens that were excised from sporadic cases of axial
myopathy[15].Furthermore,facioscapulohumeralmuscular
dystrophy with isolated axial myopathy has also been
reported [19]. Five cases of axial myopathy that were asso-
ciated with mitochondrial dysfunction have been previously
reported; however, no familial cases of mitochondrial gene
mutation have been reported [8, 11, 28, 30, 32].
In this paper, we have reported about a mitochondrial
disease that is characterized by familial late-onset pre-
dominant axial myopathy and encephalopathy. In addition,
the pathogenicity of a novel, familial, mitochondrial tRNA
gene mutation is discussed.
Methods
Subjects
Patient 1
A 73-year-old woman (Fig. 1, III-8) presenting with
abnormal posture and gait disturbance. Since the age of 63,
the patient had a slight stooping posture and a pushed-out
waist. At 68 years of age, she started using a walking stick
because of her unstable gait. She was diagnosed with
hypothyroidism by her family physician and administrated
with 25 lg/day levothyroxine; however, her symptoms did
not improve. At 70 years of age, it gradually became more
difﬁcult for her to climb the stairs. At 71 years of age, she
was admitted to another hospital. Doctors suspected
myopathy because of elevated serum CK levels. She visited
our hospital presenting with prominent paraspinal muscle
atrophy and mild proximal weakness of limbs. Hypothy-
roidism-related myopathy was suspected in her, and hence,
the levothyroxine dose was increased to 50 lg/day; how-
ever, her symptoms did not improve. She had a family
history of bent spine, i.e., in her elder sister (patient 2,
Fig. 1, III-5), mother (Fig. 1, II-3), and maternal aunt
(Fig. 1, II-4). Physical examination on arrival revealed a
marked atrophy of the paraspinal muscles and abnormal
posture (Fig. 2a, b). She also presented with right ptosis,
dysarthria, bilateral cataracts, and hearing loss. Her eye
movements were normal. But there was moderate weak-
ness of the neck ﬂexion and mild weakness of the proximal
limb muscles. Tendon reﬂexes were symmetrical, and
Babinski’s sign was absent. She had poor balance with
tandem gait without limb ataxia. Sensory systems were
intact and Romberg’s sign was negative. She scored poorly
on the attention and calculation tests that are a part of the
Mini-Mental State Examination (score: 25 points).
Laboratory data were as follows: serum CK level was
290 IU/l (normal range 45–163 IU/l), resting blood and
cerebrospinal ﬂuid (CSF) lactate levels were normal, thy-
roid-stimulating hormone levels were slightly low at
0.47 lIU/ml (normal range 0.5–5.0 lIU/ml). Under the
administration of 50 lg/day levothyroxine; antithyroglob-
ulin antibody levels were high at 7.0 U/ml (normal range
\0.3 U/ml), antithyroid peroxidase antibody levels were
high at 46.5 U/ml (normal range \0.3 U/ml), rheumatoid
factor levels were high at 152.3 IU/ml (normal value
\15.0 IU/ml), antinuclear antibody levels were mildly
elevated (titer of 1:80). Autoimmune analyses, including
anti-Jo-1, anti-RNP, anti-SS-A, and anti-SS-B, were neg-
ative. The oral glucose tolerance test (75 g) was within
normal limits, but Holter monitoring revealed high-fre-
quency premature contractions. Pure-tone audiometry
indicated sensorineural and high-frequency hearing loss.
Needle electromyographic ﬁndings of the biceps brachii
and rectus femoris muscles indicated mild myopathic fea-
tures. Computed tomography (CT) of the thoracic spinal
nerve 10 (T10) revealed severe atrophy and fatty degen-
eration of the paraspinal muscles (Fig. 2c). Brain magnetic
Fig. 1 Pedigree of the family. The arrow indicates the proband. The
affected individuals are represented by the solid black symbols; open
symbols represent healthy individuals. Gray symbols indicate indi-
viduals with elevated CK levels
776 Acta Neuropathol (2011) 121:775–783
123resonance imaging (MRI) with ﬂuid-attenuated inversion
recovery imaging showed moderate cerebellar and tem-
poro-parieto-occipital lobe atrophy (Fig. 2d). MR
spectroscopy revealed the absence of increased lactate
peaks. 123I-IMP single photon emission CT revealed
hypoperfusion that was indicative of atrophic brain lesions.
Patient 2
The elder sister of patient 1 was an 84-year-old woman
with a stooping posture presenting with tremors since the
age of 60. In her 70s she started walking with the aid of a
walking stick. At 82 years of age, she was hospitalized for
Fig. 2 a The full-length ﬁgure indicates the posture of patient 1
showing her pushed-out waist. b The dorsal view shows the marked
atrophy of the paraspinal muscles in patient 1. CT of T10 of c patient
1 (age 71), e patient 2 (age 82), and g a healthy female (age 74)
reveals the profound atrophy of the paraspinal muscles in c patient 1
and e patient 2, but not in g the healthy female. Brain MRI studies
revealed several differences between the patients 1 and 2. d Axial
FLAIR images of patient 1 show moderate cerebellar atrophy and
some cerebral cortical atrophy. f The same images of patient 2
revealing hyperintense lesions around the white matter
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123generalized seizures and disturbed consciousness. CT of
T10 revealed severe atrophy and fatty degeneration of the
paraspinal muscles (Fig. 2e). Brain MRI revealed hyper-
intense lesions around the white matter (Fig. 2f); elevated
serum and CSF lactate levels were also noted at this time.
The mitochondrial DNA analysis of the lymphocytes
did not indicate MELAS (m.3243A[G) or MERRF
(m.8344A[G) mutations. The patient’s condition remained
undiagnosed and she died at the age of 84. CK levels in all
her four sons were found to be elevated and her third son
was diagnosed with epilepsy. She and her fourth son had
also been previously diagnosed with Hashimoto thyroiditis
(Fig. 1).
Patient 1 was examined using pathological, biochemical,
and genetic analyses. The Institutional Review Board of
Kagoshima University approved this study. Patient 1 gave
the written and informed consent for her participation in
this study.
Histochemical and immunohistochemical studies
Frozen biopsies of the biceps brachii muscle specimens
were obtained from patient 1. The specimens were sliced
into 8 lm sections and placed on aminosilane-coated
slides. Histochemical and immunohistochemical proce-
dures were performed as previously described [13].
Biochemical studies
Enzyme activity levels, blue native polyacrylamide gel
electrophoresis (BN-PAGE), and other biochemical mea-
surements of the frozen muscle specimens from patient 1
were performed as previously described [6, 33, 36].
Mitochondrial DNA analysis
In case of patient 1, the total DNA was extracted from the
peripheral blood leukocytes and the frozen muscle speci-
mens using the DNeasy Blood & Tissue kit (Qiagen).
MitoChip v2.0 (The GeneChip
 Human Mitochondrial
Resequencing Array 2.0), which provides a standard assay
for the complete sequence analysis of human mitochondrial
DNA, was obtained from Affymetrix. The patient’s entire
mitochondrial DNA was sequenced using MitoChip v2.0 as
previously described [37]. Analysis of the microarray
data obtained with MitoChip v2.0 was performed using
GeneChip Sequence Analysis Software v4.0 (Affymetrix)
[24].
In order to reveal the mutations that were conﬁrmed by
MitoChip v2.0, a 465-base pair PCR product that spanned
all of the mutation sites was screened by DNA sequencing.
In brief, 50 ng of the patient’s genomic DNA was ampli-
ﬁed using the hot-start PCR method and a forward
(50-CACCATTCTCCGTGAAATCA-30) and reverse pri-
mer (50-AGGCTAAGCGTTTTGAGCTG-30)[ 5, 29]. Each
PCR product was generated under the following condi-
tions: 15 min at 95C, 42 cycles of ampliﬁcation (95C for
30 s, 61C for 30 s, and 72C for 1 min), and 30 min at
72C. Using a presequencing kit (USB, Cleveland, OH,
USA), the patient’s PCR products with abnormal elution
proﬁles were puriﬁed, and the appropriate PCR products
from relatives and control chromosomes were obtained and
sequenced by dye-terminator chemistry using an ABI
Prism 377 sequencer (Applied Biosystems, Foster City,
CA, USA). The resulting sequences were then aligned and
any mutations were evaluated using the Sequencher
sequence alignment program (Gene Codes, Ann Arbor, MI,
USA).
The polymorphic and pathogenic natures of the conﬁrmed
mutations were checked against two databases: the MITO-
MAP (http://www.mitomap.org/) and GiiB-JST mtSNP
database (http://mtsnp.tmig.or.jp/mtsnp/index.shtml).
Results
Histological and immunohistochemical
characterizations
The muscle ﬁbers ranged from 10 to 80 lm in diameter.
Sixty-nine of the 609 Gomori trichrome stained muscle
ﬁbers (11.3%) were ragged-red ﬁbers (Fig. 3a). Cyto-
chrome c oxidase (COX) activity was deﬁcient in many of
the ragged-blue ﬁbers that were stained with succinate
dehydrogenase (SDH) and COX (233 of 881 muscle ﬁbers,
26.4%) (Fig. 3b, c), and no blood vessels showing strong
SDH reactivity were observed. In NADH dehydrogenase-
reactive sections, focal decreases and increases in oxidative
enzyme activities were observed. Adenosine monophos-
phate (AMP) deaminase activity was normal. The random
checkerboard distribution of the histochemical ﬁber types
was preserved as shown in the ATPase-reactive sections.
Acid phosphatase activity was slightly high in some ﬁbers.
Muscle ﬁber glycogen contents appeared normal and the
lipid contents were slightly high in some ﬁbers. Electron
microscopy showed abnormal proliferation of mitochon-
dria with paracrystalline inclusions (Fig. 4).
Biochemical studies
All respiratory chain enzyme activities, which are expres-
sed as a percentage of the normal control values relative
to the citrate synthase activity, were greater than 20%
(Table 1). BN-PAGE revealed no abnormalities in either
the respiratory chain complexes or their molecular assem-
bly structures.
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123Mitochondrial DNA analysis
Using MitoChip v2.0, 37 missense variants were detected
in the mitochondrial DNA of the peripheral blood lym-
phocytes. All of these variants show polymorphisms and
are listed in the MITOMAP and GiiB-JST mtSNP dat-
abases. Two additional missense variants were detected in
the mitochondrial DNA of the muscle homogenate; the
variants were m.602C[T in the tRNA
Phe gene and
m.16111C[G in the D-loop. The variant m.16111C[Gi s
listed as a polymorphism, but the variant m.602C[T is not
reported in either database. The m.602C[T variant was
also conﬁrmed by direct sequencing. The sequence chro-
matogram showed a heteroplasmic m.602C[T transition in
the muscle homogenate mitochondrial tRNA
Phe gene
(Fig. 5a). The proportion of mutant mitochondrial DNA in
the muscle was 64.7 ± 1.2% (mean ± SD; the operation
was performed thrice). Mutant mitochondrial DNA was not
detected in the blood lymphocytes when measured using
real-time ampliﬁcation refractory mutation system quanti-
tative PCR analysis (RT-ARMS qPCR), as previously
described [2, 10]. Healthy Japanese controls (n = 100) did
not show these mutations in their blood lymphocytes, at
least not within the limits of Sanger’s method for DNA
sequencing.
Discussion
A novel mitochondrial tRNA
Phe gene mutation was iden-
tiﬁed in a patient with late-onset predominant axial
myopathy and cerebellar ataxia (patient 1). She presented
with a maternal history of bent spine, and her elder sister
presented with elevated lactate levels, severe paraspinal
muscle atrophy, and epilepsy. Furthermore, the sister’s four
Fig. 3 Histochemical analysis of the right biceps brachii muscle.
a Gomori trichrome staining reveals typical ragged-red ﬁbers.
Histochemical analysis of serial sections of samples stained with
b SDH or c COX shows a number of ragged-blue ﬁbers with COX
deﬁciency. a2c Bar 100 lm
Fig. 4 Electron micrograph of abnormal mitochondria in the right
biceps brachii muscle. Abnormal mitochondria with paracrystalline
inclusions that are suggestive of mitochondrial myopathy are shown.
a bar 1 lm, b bar 500 nm
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123sons presented with elevated CK levels, among which one
had epilepsy. Patient 1 also presented with other symptoms
associated with mitochondrial disease, including mild
blepharoptosis, cataracts, hearing loss, and arrhythmia.
Morphological examination revealed many ragged-red
ﬁbers and a partial deﬁciency in COX activity. One of the
major diagnostic criteria for respiratory chain disorders in
adults is less than 20% activity in any of the tissue com-
plexes, but the data of the present study did not fulﬁll this
condition [4]. However, the activities of complexes I
(43.4%) and IV (54.7%) were lower than those of the other
complexes. The decreased activities of complexes I and IV
are probably due to the deﬁciency in COX activity that was
measured in the muscle ﬁbers. These clinical, morpholog-
ical, and biochemical manifestations indicate that the
patient most likely had a mitochondrial disease.
The marked atrophy of the paraspinal muscles was the
most interesting feature found in patients 1 and 2. Axial
myopathy has been deﬁned as muscle weakness that is
limited to the spinal and neck muscles [21]. Therefore, the
symptoms of patient 1 are incompatible with pure axial
myopathy because of the muscle weakness and mitochon-
drial abnormalities that were observed in the biceps brachii
muscle. The most characteristic feature of axial myopathy
is the remarkable atrophy of the paraspinal muscles rather
than the atrophy of the muscles of the limbs, which is
Table 1 Enzymatic activities for mitochondrial respiratory complexes in patient 1
CI activity (CI/CS) CII activity (CII/CS) CIII activity (CIII/CS) CIV activity (CIV/CS) CS activity
Patient 1 0.1938 (0.7027) 0.2723 (0.9874) 1.2737 (4.6192) 0.0579 (0.21) 0.2757
Control 0.3194 (1.6183) 0.2751 (1.3444) 1.3132 (6.5512) 0.0826 (0.3840) 0.2151
Patient 1/control ratio 60.7% (43.4%) 98.9% (73.4%) 97.0% (70.5%) 70.1% (54.7%)
Enzymatic activities for individual mitochondrial respiratory complexes are given in nmol/min protein, and represent percentage of normal
control (n = 10) mean relative to a reference enzyme of citrate synthase (CS)
The activities are relatively low in complex I and complex IV compared with other complexes
CI complex I, CII complex II, CIII complex III, CIV complex IV
Fig. 5 a Sequence chromatogram of the mitochondrial DNA region
that encompasses the m.602C[T alteration (asterisk) that was
obtained from the skeletal muscle of patient 1 (reverse complement).
b Schematic diagram of the mitochondrial tRNA
Phe cloverleaf
structure showing previously reported mutations and the m.602C[T
alteration in the D-stem. c Comparison of mitochondrial tRNA
Phe
from different species. Base pairs, including the 602 nucleotides, are
shown in boxes
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123different from the clinical symptoms of conventional
mitochondrial myopathy. Thus, based on the available
evidence, we believe that patients 1 and 2 can be diagnosed
with mitochondrial predominant axial myopathy.
Axial myopathy may occur secondary to various dis-
eases. However, only ﬁve cases of mitochondrial axial
myopathy associated with the prominent involvement of
the extensor muscles of the spine have been previously
reported (Table 2)[ 8, 11, 28, 30, 32]. All these cases
presented with abnormal trunk ﬂexion that developed
during walking and disappeared when the patient was in a
supine position. In the cases described here, only patient 2
presented with camptocormia. These common symptoms,
including late-onset, mildly elevated serum CK levels,
ragged-red ﬁbers, and the partial deﬁciency in COX
activities, were observed in patient 1 and also in the above
mentioned cases. However, biochemical analysis was per-
formed in only one case that showed deﬁciencies in
complexes I and III [32]. No case has been previously
reported that describes a family history of similar symp-
toms. In addition, no genetic cause of any mitochondrial
axial myopathy has been previously reported.
This study is unable to conclusively prove or disprove
the pathogenicity of the m.602C[T mutation. However,
three reasons that support the pathogenicity of this mutation
are apparent. First, the heteroplasmic m.602C[T point
mutation disrupts a conserved Watson–Crick cytosine–
guanine (C–G) base pairing within the D-stem of the
mitochondrial tRNA
Phe gene, which would most likely
affect the stability of the secondary structure of mitochon-
drial tRNA (Fig. 5b). Almost 94% of mitochondrial tRNA
pathogenic mutations occur in this stem structure, and the
disruption of Watson–Crick C–G base pairing is a signiﬁ-
cantly more common feature of pathogenic mutations than
neutral variants [23]. Second, after performing a sequence
homology search using CLUSTALW (http://clustalw.
ddbj.nig.ac.jp/top-j.html), it was determined that this base
pairing is largely conserved in other species as C–G
or adenine–thymine base pairings (Fig. 5c). Third, the
mutation is heteroplasmic and present in the affected skel-
etal muscles but not in the peripheral blood lymphocytes.
Almost all pathogenic mitochondrial tRNA mutations in
clinically affected tissues have a high proportion of het-
eroplasmy compared with unaffected tissues [23].
However, the decreased activities of complexes I and IV
that were observed during the biochemical examination
cannot be completely explained by the disruption in
mitochondrial protein synthesis that could have been
caused by the mitochondrial tRNA mutation. In addition,
data obtained from the single muscle ﬁber analyses were
limited due to the small sample size, and therefore, are not
sufﬁcient to prove the pathogenicity of the m.602C[T
mutation.
Any additional evidence of the pathogenicity of the
cybrid cells was not obtained. Therefore, 10 points (out of a
maximum score of 20 points) was applied to the scoring
criteria of the mitochondrial tRNA mutations listed in
MITOMAP, which indicated that the m.602C[T mutation
is possibly pathogenic [23].
The mechanism of late-onset axial myopathy induced by
mitochondrial dysfunction is unclear. Nine pathogenic
mutations in the mitochondrial tRNA
Phe gene have been
previously described in various diseases (Fig. 5b), includ-
ing a late-onset neuromuscular disease but not axial
myopathy [7, 9, 12, 14, 17, 18, 22, 25, 34, 35]. A probable
etiological mechanism for the presentation of such a
myopathy in the elderly is the accumulation of mitochon-
drial tRNA pathogenic mutations that affect aging tissues
[9]. If it is possible to get any information on the patho-
logical status of the primarily affected muscles, this would
perhaps be as informative as the differential involvement of
the biceps and paraspinal muscles. Unfortunately, these
data could not be obtained due to the remarkable fatty
degeneration of the paraspinal muscles.
The patients described in this report are characterized by
the combination of axial myopathy and CNS involvement.
One report about a parkinsonian patient with mitochondrial
axial myopathy suggested that mitochondrial dysfunction
Table 2 Clinical characteristics of patients with paraspinal muscle atrophy from mitochondrial myopathy
Age/sex [Ref.] Onset age Family history CK (IU/l) RRF COX deﬁciency mtDNA mutation Neurological deﬁcit
73/F [patient 1] 63 ? 290 ?? 602C[T Cerebellar ataxia
84/F [patient 2] 60 ? 474 NE NE NE Encephalopathy
65/M [32]5 9 - 245 ?? NR -
65/M [30]6 2 N R N R ?? NR Parkinsonism
78/M [11] 78 NR 501 ?? NR -
64/M [28] NR NR Elevated ?? NR -
55/M [8] NR NR Normal ?? NR -
M male, F female, CK creatine kinase, RRF ragged-red ﬁber, NR not reported, NE not evaluated, COX cytochrome c oxidase, mtDNA
mitochondrial DNA, Ref reference
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123may lead to both axial myopathy and parkinsonism [30]. In
the patients described here, CNS involvement was similar
to that observed in myoclonus epilepsy with ragged-red
ﬁber (MERRF) due to the accompanying cerebellar atro-
phy and epilepsy. In fact, MERRF has been previously
reported to be associated with pathogenic mutations of the
mitochondrial tRNA
Phe gene [22].
Finally, mitochondrial dysfunction might be implicated
in the development of Hashimoto thyroiditis in patients 1
and 2 and in the fourth son of patient 2; the relationship
between mitochondrial diseases and Hashimoto thyroiditis
has been previously described [3, 20, 26, 27].
In summary, this is the ﬁrst report about familial mito-
chondrial disease with late-onset predominant axial
myopathy and encephalopathy, which were conﬁrmed by
clinical and histological ﬁndings. This case expands the
phenotypic spectrum of mitochondrial diseases. Future
studies on the novel mitochondrial tRNA
Phe 602C[T
mutation may contribute to the understanding of late-onset
predominant axial myopathy and encephalopathy.
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